2nd Oct 2018 16:59
2 October 2018
Clinigen Group plc
Clinigen Group Completes Acquisition of CSM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today announces that it has completed the acquisition of CSM Parent, Inc. ('CSM'), which was announced on 27 September 2018 (the "Acquisition").
Following Admission of the Placing Shares on 1 October 2018 (details of the Placing having been announced by the Company on 27 September 2018 to coincide with the announcement of the Acquisition), the Company now has in issue 131,949,754 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 131,949,754 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information, please contact:
Clinigen Group plc | Tel:+44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Martin Abell, Group Chief Financial Officer Matt Parrish, Head of Investor Relations | |
Numis Securities Limited (Nominated Adviser, Joint Financial Adviser and Joint Corporate Broker to Clinigen) | Tel: +44 (0)20 7260 1000 |
Michael Meade James Black Freddie Barnfield | |
RBC Capital Markets (Joint Financial Adviser and Joint Corporate Broker to Clinigen) | Tel: +44 (0)20 7653 4000 |
Marcus Jackson Thomas Stockman Elliot Thomas | |
Instinctif Partners (FPR Adviser to Clinigen) | Tel: +44 (0)20 7457 2020 |
Adrian Duffield Melanie Toyne Sewell Alex Shaw |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L